Aíma develops advanced liquid biopsy tests for minimal residual disease and early cancer detection. Our whole-genome methylation and fragmentomics platform combines AI with ultra-sensitive sequencing to detect cancer DNA and determine its tissue of origin. We collaborate with leading clinical centers to bring faster, more accurate and more accessible cancer diagnostics to patients.
| Website | http://www.aima-diagnostics.com |
| Employees | 7 (5 on RocketReach) |
| Founded | 2025 |
| Industry | Pharmaceutical Manufacturing |
Looking for a particular Aíma employee's phone or email?
Michael Blum is the Co-founder and CSO of Aíma.
5 people are employed at Aíma.
Aíma is based in Grenoble, Auvergne-Rhône-Alpes.